All In Biotech

Drug Trial Radar · NCT07408232

A Phase 1/2 Study in Healthy Volunteers and Participants With Autosomal Dominant Retinitis Pigmentosa (RHO-adRP)

A Phase 1/2, First-in-Human Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of OCT-980 in Healthy Volunteers and Participants With Autosomal Dominant Retinitis Pigmentosa

Last checked: Nov 20, 2026Latest source record: Sep 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

18

Planned (sponsor's estimate)

Start

Mar 10, 2026

Primary completion

Nov 1, 2028

Study completion Nov 1, 2028

Sponsor

Lead sponsor
Octant, Inc.Industry
Sponsor type
Industry
First posted
Feb 13, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This integrated Ph1/2 clinical study is to assess the safety, tolerability and pharmacokinetics (PK), pharmacodynamics (PD) and efficacy of OCT-980 in healthy volunteers and participants with RHO-adRP.

Conditions

  • Retinitis Pigmentosa

Interventions

  • Phase 1b/2: Cohort 1 - OCT-980 TabletDrug

    OCT-980 tablets administered orally once daily at dose levels specified in the protocol

  • Phase 1b/2: Cohort 2 - OCT-980 TabletDrug

    OCT-980 tablets administered orally once daily at dose levels specified in the protocol

  • Phase 1b/2: Cohort 3 - OCT-980 TabletDrug

    OCT-980 tablets administered orally once daily at dose levels specified in the protocol

  • Phase 1b/2: Cohort 4 - OCT-980 TabletDrug

    OCT-980 tablets administered orally once daily at dose levels specified in the protocol

  • Phase 1b/2: Cohort 5 - OCT-980 TabletDrug

    OCT-980 tablets administered orally once daily at dose levels specified in the protocol

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety and tolerability of multiple doses (Phase 1b/2) of OCT-980 in participants with a genetic diagnosis of RHO-adRP.Time frame: Time Frame: From Baseline to Week 60 (Ph 1b/2)

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Casey Eye Institute

    Portland, Oregon · Recruiting

  • Retina Foundation of the Southwest

    Dallas, Texas · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.